TECX biotech catalysts & pipeline

TECTONIC THERAPEUTIC INC · Data as of 2026-09-08

Upcoming catalysts

TX2100 — Topline data

Q3 2026

TX2100, a potential treatment for Hereditary Hemorrhagic Telangiectasia ("HHT"), completed dosing of the six single dose healthy volunteer cohorts in the Phase 1a clinical trial, with topline results anticipated by end of Q3 2026

Source filing

TX45 — Topline data

Q1 2027

APEX patient enrollment is complete with topline results expected early Q1 2027.

Source filing

Explore the free biotech catalyst calendar